273 related articles for article (PubMed ID: 15166968)
21. Peritoneovenous shunts for palliation of the patient with malignant ascites.
Schumacher DL; Saclarides TJ; Staren ED
Ann Surg Oncol; 1994 Sep; 1(5):378-81. PubMed ID: 7531600
[TBL] [Abstract][Full Text] [Related]
22. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
Membreno F; Baez AL; Pandula R; Walser E; Lau DT
J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
[TBL] [Abstract][Full Text] [Related]
23. Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts.
Tomiyama K; Takahashi M; Fujii T; Kunisue H; Kanaya Y; Maruyama S; Yokoyama N; Nakao A; Soda M; Shimizu N
Anticancer Res; 2006; 26(3B):2393-5. PubMed ID: 16821622
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascites.
Tokue H; Takeuchi Y; Arai Y; Sofue K; Sakamoto N; Tsushima Y; Endo K
World J Surg Oncol; 2011 Jul; 9():82. PubMed ID: 21777451
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
Tan HK; James PD; Sniderman KW; Wong F
J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
[TBL] [Abstract][Full Text] [Related]
26. Morbidity and mortality after peritoneovenous shunt surgery for refractory ascites.
Rubinstein D; McInnes I; Dudley F
Gut; 1985 Oct; 26(10):1070-3. PubMed ID: 4054706
[TBL] [Abstract][Full Text] [Related]
27. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score.
Trotter JF; Suhocki PV; Rockey DC
Am J Gastroenterol; 1998 Oct; 93(10):1891-4. PubMed ID: 9772050
[TBL] [Abstract][Full Text] [Related]
28. Peritoneovenous shunt for refractory ascites: operative complications and long-term results.
Bernhoft RA; Pellegrini CA; Way LW
Arch Surg; 1982 May; 117(5):631-5. PubMed ID: 7073482
[TBL] [Abstract][Full Text] [Related]
29. [Transjugular intrahepatic portosystemic shunt for refractory ascites: results in 50 patients].
Kanazawa H; Narahara Y; Fukuda T; Kondo C; Harimoto H; Matsushita Y; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Osada Y; Nakatsuka K; Sakamoto C
Nihon Shokakibyo Gakkai Zasshi; 2009 Mar; 106(3):356-69. PubMed ID: 19262049
[TBL] [Abstract][Full Text] [Related]
30. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices.
Rosemurgy AS; Goode SE; Zwiebel BR; Black TJ; Brady PG
Ann Surg; 1996 Sep; 224(3):378-84; discussion 384-6. PubMed ID: 8813266
[TBL] [Abstract][Full Text] [Related]
31. Peritoneovenous shunt function 2-6 years after insertion for cirrhotic ascites.
Stanley MM; VanDrunen M; Greenlee HB
ASAIO Trans; 1989; 35(2):170-4. PubMed ID: 2730817
[TBL] [Abstract][Full Text] [Related]
32. Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation.
Abouljoud M; Yoshida A; Kim D; Jerius J; Arenas J; Raoufi M; Brown K; Moonka D
Transplant Proc; 2005 Mar; 37(2):1248-50. PubMed ID: 15848685
[TBL] [Abstract][Full Text] [Related]
33. Surgical shunts and TIPS for variceal decompression in the 1990s.
Henderson JM; Nagle A; Curtas S; Geisinger M; Barnes D
Surgery; 2000 Oct; 128(4):540-7. PubMed ID: 11015086
[TBL] [Abstract][Full Text] [Related]
34. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: preliminary results.
Kovács A; Schepke M; Heller J; Schild HH; Flacke S
Cardiovasc Intervent Radiol; 2010 Apr; 33(2):290-6. PubMed ID: 19730936
[TBL] [Abstract][Full Text] [Related]
35. Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis.
Gaba RC; Parvinian A; Casadaban LC; Couture PM; Zivin SP; Lakhoo J; Minocha J; Ray CE; Knuttinen MG; Bui JT
Clin Radiol; 2015 May; 70(5):e51-7. PubMed ID: 25758602
[TBL] [Abstract][Full Text] [Related]
36. Implantation of a Denver shunt by left subclavian approach for preventing kinking.
Oida T; Mimatsu K; Kawasaki A; Kanou H; Kuboi Y; Matsuoka S; Amano S
Hepatogastroenterology; 2009; 56(93):1074-7. PubMed ID: 19760944
[TBL] [Abstract][Full Text] [Related]
37. Peritoneovenous shunting for malignant ascites.
Wickremesekera SK; Stubbs RS
N Z Med J; 1997 Feb; 110(1037):33-5. PubMed ID: 9066565
[TBL] [Abstract][Full Text] [Related]
38. An Algorithm for Management After Transjugular Intrahepatic Portosystemic Shunt Placement According to Clinical Manifestations.
Kim SK; Belikoff BG; Guevara CJ; Park SJ
Dig Dis Sci; 2017 Feb; 62(2):305-318. PubMed ID: 28058594
[TBL] [Abstract][Full Text] [Related]
39. Does advanced chronic kidney disease impact transjugular intrahepatic portosystemic shunt efficacy and safety?
Lakhoo J; Gunasekaran SS; Lokken RP; Lipnik AJ; Ray CE; Bui JT; Gaba RC
Acta Gastroenterol Belg; 2017; 80(2):243-248. PubMed ID: 29560689
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis.
Chen RP; Zhu Ge XJ; Huang ZM; Ye XH; Hu CY; Lu GR; Lu DY; Phemba IL
J Clin Gastroenterol; 2014 Mar; 48(3):290-9. PubMed ID: 24030734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
